drugset / Trial / NCT02825147

Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma

NCT02825147

Phase 2 Completed 40 enrolled Ruijin Hospital
NaSingle-groupOpen-labelTreatment

Summary

Extranodal NK/T cell lymphoma is an aggressive tumor with higher incidence in Asia.Traditional CHOP/CHOP-like regiment can't produce satisfied outcome for the patients. Asparaginase-based treatment has been demonstrated as promising response rate and survival superiority. Stage-specified regimen may bring out exciting efficacy with good safety.

Timeline

Start
2013-09
Primary completion
2016-03
Completion
2017-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 1000 mg/m2
Subject Pegaspargase Protein / enzyme biologic 2500 unknown
Background Dexamethasone Small molecule 40 mg
Background Etoposide Small molecule 100 mg